Living with eczema isn’t just a physical challenge—it affects mental health, confidence, and daily life. That’s why ATOPIYO, Japan’s leading eczema app, is launching in the U.S., where 31 million people are affected. With a growing community of over 29,000 users, ATOPIYO empowers individuals with eczema to track their symptoms, document treatment progress, and connect with others—all through a simple and intuitive visual platform.
A New Way to Manage Eczema
During the hot summer months, monitoring eczema symptoms becomes especially important. ATOPIYO makes this easier by allowing users to photograph their skin, meals, and medications—helping them visualize their treatment journey and share it with others over time.
“This is the best eczema management app I’ve used so far. I hope you continue improving it! Being able to compare my symptoms with others who share the same condition—it’s groundbreaking.”— Google Play reviewer (JP)
3 Key Features:
Visual Tracking – Snap photos to easily record and organize symptoms, diet, and medication.
Peer Support – Share experiences and connect with others facing similar struggles.
Anonymous & Free – Secure platform with no cost barriers to care.
“Posting anonymously helps me find others with similar symptoms and treatments—it’s incredibly helpful. Just seeing someone say ‘I get it’ when I’m feeling down from the itching or appearance is a relief. I feel less alone and more motivated to get better. Recording and sharing gives me a surprising sense of positivity. I also hope these posts contribute to new treatment development.” — App Store reviewer (JP)


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































